Eiji Kojima

2.4k total citations
92 papers, 1.9k citations indexed

About

Eiji Kojima is a scholar working on Pulmonary and Respiratory Medicine, Infectious Diseases and Virology. According to data from OpenAlex, Eiji Kojima has authored 92 papers receiving a total of 1.9k indexed citations (citations by other indexed papers that have themselves been cited), including 25 papers in Pulmonary and Respiratory Medicine, 15 papers in Infectious Diseases and 13 papers in Virology. Recurrent topics in Eiji Kojima's work include HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (13 papers) and Lung Cancer Treatments and Mutations (9 papers). Eiji Kojima is often cited by papers focused on HIV Research and Treatment (13 papers), HIV/AIDS drug development and treatment (13 papers) and Lung Cancer Treatments and Mutations (9 papers). Eiji Kojima collaborates with scholars based in Japan, United States and Poland. Eiji Kojima's co-authors include T Shirasaka, Robert Yarchoan, Hiroaki Mitsuya, Mark F. Kavlick, Tadao Hasegawa, Ken‐ichi Isobe, Sudhichai Chokekijchai, Wei Gao, Bidyut Roy and Eddy Arnold and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Physical Review Letters and Nature Genetics.

In The Last Decade

Eiji Kojima

87 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eiji Kojima Japan 23 667 661 461 304 256 92 1.9k
Kenichi Imai Japan 28 533 0.8× 418 0.6× 717 1.6× 116 0.4× 329 1.3× 155 2.8k
Gareth J. Thomas United Kingdom 14 528 0.8× 444 0.7× 493 1.1× 63 0.2× 96 0.4× 39 1.9k
Akihisa Kato Japan 32 279 0.4× 188 0.3× 795 1.7× 298 1.0× 1.8k 6.9× 155 3.2k
John J. Toole United States 19 1.4k 2.1× 908 1.4× 2.9k 6.3× 81 0.3× 645 2.5× 20 5.5k
Jeffrey M. Harris United States 26 209 0.3× 245 0.4× 480 1.0× 1.7k 5.5× 352 1.4× 64 4.8k
Gregory Mullen United Kingdom 33 155 0.2× 143 0.2× 686 1.5× 327 1.1× 315 1.2× 77 3.6k
M. R. Young United States 23 399 0.6× 107 0.2× 744 1.6× 166 0.5× 499 1.9× 72 2.5k
Youdong Mao China 24 215 0.3× 343 0.5× 2.1k 4.5× 35 0.1× 245 1.0× 44 2.8k
Qi Fan China 28 234 0.4× 212 0.3× 851 1.8× 35 0.1× 297 1.2× 118 2.9k
Huilan Zhang China 23 599 0.9× 76 0.1× 429 0.9× 483 1.6× 152 0.6× 113 2.0k

Countries citing papers authored by Eiji Kojima

Since Specialization
Citations

This map shows the geographic impact of Eiji Kojima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiji Kojima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiji Kojima more than expected).

Fields of papers citing papers by Eiji Kojima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eiji Kojima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiji Kojima. The network helps show where Eiji Kojima may publish in the future.

Co-authorship network of co-authors of Eiji Kojima

This figure shows the co-authorship network connecting the top 25 collaborators of Eiji Kojima. A scholar is included among the top collaborators of Eiji Kojima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiji Kojima. Eiji Kojima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Hase, Tetsunari, Toru Hara, Tomoki Kimura, et al.. (2023). Adjustment of creatinine clearance for carboplatin dosing in Calvert's formula and clinical efficacy for lung cancer. Cancer Medicine. 12(15). 15955–15969. 2 indexed citations
2.
3.
Kimura, Tomoki, Hiroyuki Taniguchi, Naohiro Watanabe, et al.. (2016). Phase II Study of Carboplatin and Pemetrexed in Advanced EGFR-wild-type Non-squamous Non-small Cell Lung Cancer: The Central Japan Lung Study Group Trial 0906.. PubMed. 36(4). 1767–71. 4 indexed citations
4.
Takahashi, Kosuke, Hiroshi Saito, Yoshinori Hasegawa, et al.. (2014). First-line gefitinib therapy for elderly patients with non-small cell lung cancer harboring EGFR mutation: Central Japan Lung Study Group 0901. Cancer Chemotherapy and Pharmacology. 74(4). 721–727. 27 indexed citations
5.
Morise, Masahiro, Hiroyuki Taniguchi, Hideo Saka, et al.. (2014). Phase II study of erlotinib for previously treated patients with EGFR wild-type non-small-cell lung cancer, following EGFR mutation status reevaluation with the Scorpion Amplified Refractory Mutation System. Molecular and Clinical Oncology. 2(6). 991–996. 7 indexed citations
6.
Tomita, Yoshiyuki, et al.. (2012). Development and Applications of Sumitomo Precision Stage Technologies for FPD Process. Journal of the Japan Society for Precision Engineering. 78(2). 117–121. 15 indexed citations
7.
Kojima, Eiji, et al.. (2011). Prospective evaluation of the relationship between acute exacerbations of COPD and gastroesophageal reflux disease diagnosed by questionnaire. Respiratory Medicine. 105(10). 1531–1536. 34 indexed citations
8.
Hiramatsu, Tetsuo, et al.. (2010). A Case of Lung Cancer with Epipharyngeal Metastasis. Haigan. 50(1). 33–36.
9.
Hiramatsu, Tetsuo, et al.. (2008). Management of spontaneous pneumomediastinum based on clinical experience of 25 cases. Respiratory Medicine. 102(9). 1329–1334. 76 indexed citations
10.
Hiramatsu, Tetsuo, et al.. (2007). Purpura Fulminans Due to Pneumococcal Pneumonia in a Healthy Adult: A Case Report. Kansenshogaku zasshi. 81(2). 194–199. 1 indexed citations
11.
Kojima, Eiji & S. Takeyama. (2006). Newly Designed Destructive Magnetic Coils for Mega-Gauss Fields at ISSP. 217–226. 1 indexed citations
12.
Hasegawa, Yoshinori, Hengyi Xiao, Masataka Haneda, et al.. (2003). GADD34 induces p53 phosphorylation and p21/WAF1 transcription. Journal of Cellular Biochemistry. 90(6). 1242–1249. 47 indexed citations
13.
Takeuchi, Akihide, Yuji Mishina, Osamu Miyaishi, et al.. (2003). Heterozygosity with respect to Zfp148 causes complete loss of fetal germ cells during mouse embryogenesis. Nature Genetics. 33(2). 172–176. 81 indexed citations
14.
Kojima, Eiji. (2001). Evolving Technologies:Strategies Found in Recent Eucalyptus and Acacia Tree Farms Pursuing Intensive Agriculture. 55(7). 1 indexed citations
15.
Fujii, Yuji, R Mukai, Kazuyasu Mori, et al.. (1997). Efficacy of 6-Chloro-2',3'-Dideoxyguanosine (6-Cl-ddG) on Rhesus Macaque Monkeys Chronically Infected With Simian Immunodeficiency Virus (SIVmac239). Journal of Acquired Immune Deficiency Syndromes & Human Retrovirology. 16(5). 313–317. 5 indexed citations
16.
17.
Husson, Robert N., et al.. (1995). Vertical transmission of human immunodeficiency virus type 1: Autologous neutralizing antibody, virus load, and virus phenotype. The Journal of Pediatrics. 126(6). 865–871. 47 indexed citations
18.
Kageyama, Seiji, Eiji Kojima, Takuma Shirasaka, et al.. (1994). A C 2 Symmetry-Based HIV Protease Inhibitor, A77003, Irreversibly Inhibits Infectivity of HIV-1 In Vitro. AIDS Research and Human Retroviruses. 10(6). 735–743. 22 indexed citations
19.
Anderson, Barry, Takuma Shirasaka, Eiji Kojima, Robert Yarchoan, & Hiroaki Mitsuya. (1994). Identification of drug-related genotypic changes in HIV-1 from serum using the selective polymerase chain reaction. Antiviral Research. 25(3-4). 245–258. 4 indexed citations
20.
Shirasaka, Takuma, Eiji Kojima, Shizuko Aoki, et al.. (1991). Escherichia coli mediated biosynthesis and in vitro anti-HIV activity of lipophilic 6-halo-2',3'-dideoxypurine nucleosides. Journal of Medicinal Chemistry. 34(5). 1606–1612. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kenichi Imai Breakdown of academic impact, for papers by Gareth J. Thomas Breakdown of academic impact, for papers by Akihisa Kato Breakdown of academic impact, for papers by John J. Toole Breakdown of academic impact, for papers by Jeffrey M. Harris Breakdown of academic impact, for papers by Gregory Mullen Breakdown of academic impact, for papers by M. R. Young Breakdown of academic impact, for papers by Youdong Mao Breakdown of academic impact, for papers by Qi Fan Breakdown of academic impact, for papers by Huilan Zhang
Rankless by CCL
2026